{
  "id": "mcrc-egfr-main",
  "display_name": "mCRC RAS/BRAF WT (Main)",
  "cohort": "Metastatic Colorectal Cancer, RAS/BRAF Wild Type, Q1 2023",
  "insight_type": "Treatment Patterns by Regimen",
  "summary": "EGFR inhibitor utilization is at 65% for eligible patients with RAS/BRAF wild type mCRC, below NCCN guidelines recommendation of 80%.",
  "recommendation": "Increase appropriate utilization of EGFR inhibitors in RAS/BRAF wild type mCRC patients.",
  "financial_impact": 250000,
  "financial_impact_description": "Optimizing EGFR inhibitor use could improve outcomes and generate approximately $250,000 in annual savings through improved progression-free survival.",
  "peer_financial_impact": 320000,
  "peer_financial_impact_description": "Your organization trails peer benchmarks, with a potential financial opportunity of $320,000 annually.",
  "action_steps": [
    "Review molecular testing protocols to ensure all eligible patients receive RAS/BRAF testing",
    "Implement clinical decision support alerts for eligible patients",
    "Conduct provider education on NCCN guidelines for mCRC"
  ],
  "peer_action_steps": [
    "Benchmark against top-performing organizations",
    "Implement a targeted improvement plan",
    "Monitor both testing rates and appropriate EGFR inhibitor use"
  ],
  "chart_data": {
    "categories": ["Cetuximab", "Panitumumab", "Bevacizumab", "No biologic", "Other"],
    "values": [40, 25, 20, 10, 5],
    "peer_values": [50, 30, 15, 3, 2],
    "target_values": [55, 25, 15, 5, 0]
  },
  "drilldowns": []
} 